Europe Non-Hodgkin Lymphoma Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Type (Chemotherapy and Targeted Therapy), By Cell Type (B-Cell Lymphomas and T-Cell Lymphoma), and Europe Non-Hodgkin Lymphoma Therapeutics Market Insights, Industry Trend, Forecasts to 2033.

Europe Non-Hodgkin Lymphoma Therapeutics Market Insights Forecasts to 2033

• The Europe Non-Hodgkin Lymphoma Therapeutics Market Size is Growing at a CAGR of 8.06% from 2023 to 2033
• The Europe Non-Hodgkin Lymphoma Therapeutics Market Size is Expected to Hold a Significant Share by 2033

The Europe Non-Hodgkin Lymphoma Therapeutics Market Size is Anticipated to Hold a Significant Share by 2033, growing at a CAGR of 8.06% from 2023 to 2033.

Market Overview

The market for non-Hodgkin lymphoma (NHL) therapies in Europe is the sector of the economy that produces, manufactures, and distributes therapies for the treatment of non-Hodgkin lymphoma, a diverse group of tumors that arise in the lymphatic system. All available treatment options for NHL are included in the market, including immunotherapy, chemotherapy, targeted therapy, stem cell therapy, and radiation therapy. The Europe NHL therapeutics market is experiencing growth due to factors such as increasing NHL incidence and population age, customized medicine advancements, and combination therapies. Increased awareness of NHL, improved diagnostic methods, and increased healthcare spending contribute to market development. Government programs and funding initiatives are crucial for the growth of the market. The European Union and health agencies support clinical trials and research on novel treatments, while approval bodies like the European Medicines Agency streamline new drug approvals. These measures stimulate private and public investment, promoting innovation and better access to leading-edge treatments for patients.

Report Coverage

This research report categorizes the market for the Europe non-Hodgkin lymphoma therapeutics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the Europe non-Hodgkin lymphoma therapeutics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the Europe non-Hodgkin lymphoma therapeutics market.

Driving Factors

The rising incidence of the illness, particularly in the elderly, is one of the main factors driving the non-Hodgkin lymphoma therapeutics market in Europe. New revolutionary medicines, including immunotherapies and targeted therapies, have been developed as a result of improved medical technology and research. These therapies are improving patient outcomes and driving market expansion. The need for efficient treatments is further increased by the expanding availability of these novel therapeutics and the rising recognition of the need for early diagnosis. Additionally, the market grows as a result of pharmaceutical companies' significant R&D expenditures, which help propel the introduction of new drugs.

Restraining Factors

The price of NHL treatment, particularly newer targeted and immunotherapies, is a significant limiting factor, especially in economies with limited health budgets or the uninsured. The regulatory approval time in Europe may slow the release of latest therapies, posing challenges to market growth. Side effects and toxicity of certain treatments may also affect patient compliance.

Market Segmentation

The Europe non-Hodgkin lymphoma therapeutics market share is classified into type and cell type.

• The targeted therapy segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR during the forecast period.

The Europe non-Hodgkin lymphoma therapeutics market is segmented by type into chemotherapy and targeted therapy. Among these, the targeted therapy segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR during the forecast period. Traditional chemotherapy for NHL treatment is being replaced by targeted therapies like kinase inhibitors and monoclonal antibodies. These therapies target cancer cells while sparing healthy ones, reducing adverse effects. Their effectiveness and personalized treatment plans are gaining popularity, supporting their market dominance due to their perceived patient-friendliness and success.

• The B-cell lymphomas segment accounted for the highest share in 2023 and is expected to grow at a significant CAGR during the forecast period.

Based on the cell type, the Europe non-Hodgkin lymphoma therapeutics market is divided into B-cell lymphomas and T-cell lymphoma. Among these, the B-cell lymphomas segment accounted for the highest share in 2023 and is expected to grow at a significant CAGR during the forecast period. B-cell lymphomas, including DLBCL and follicular lymphoma, are the most common NHL cases, leading to increased demand for B-cell malignancy-targeting therapies. The extensive research on B-cell targeted therapies, such as monoclonal antibodies and CAR-T cell therapies, has dominated the market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Europe non-Hodgkin lymphoma therapeutics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Roche Holding AG
• Novartis International AG
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• AbbVie Inc.
• Amgen Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Pfizer Inc.
• Celgene Corporation
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In March 2024, the European Medicines Agency (EMA) approved odronextamab (marketed as Ordspono), a bispecific antibody that targets CD20 and CD3, for Regeneron Pharmaceuticals' use in treating relapsed or refractory B-cell non-Hodgkin lymphoma. The therapeutic choices for NHL patients in Europe have significantly improved since this approval.

Market Segment

This study forecasts revenue at Europe, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Europe non-Hodgkin lymphoma therapeutics market based on the below-mentioned segments:

Europe Non-Hodgkin Lymphoma Therapeutics Market, By Type

• Chemotherapy
• Targeted Therapy

Europe Non-Hodgkin Lymphoma Therapeutics Market, By Cell-Type

• B-Cell Lymphomas
• T-Cell Lymphoma